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REVIEW
Human epidermal growth factor receptor targeted inhibitors
for the treatment of ovarian cancer
Maria Bonello, Andrew Harvey Sims, Simon Peter Langdon
Cancer  Research  UK  Edinburgh  Center  and  Division  of  Pathology  Laboratory,  MRC  Institute  of  Genetics  and  Molecular
Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
 
ABSTRACT Ovarian cancer is the second most lethal gynecological cancer worldwide and while most patients respond to initial therapy, they
often  relapse  with  resistant  disease.  Human  epidermal  growth  factor  receptors  (especially  HER1/EGFR  and  HER2/ERBB2)  are
involved  in  disease  progression;  hence,  strategies  to  inhibit  their  action  could  prove  advantageous  in  ovarian  cancer  patients,
especially in patients resistant to first line therapy. Monoclonal antibodies and tyrosine kinase inhibitors are two classes of drugs
that  act  on  these  receptors.  They  have  demonstrated  valuable  antitumor  activity  in  multiple  cancers  and  their  possible  use  in
ovarian  cancer  continues  to  be  studied.  In  this  review,  we  discuss  the  human  epidermal  growth  factor  receptor  family;  review
emerging  clinical  studies  on  monoclonal  antibodies  and  tyrosine  kinase  inhibitors  targeting  these  receptors  in  ovarian  cancer
patients; and propose future research possibilities in this area.
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Introduction
Ovarian  cancer  is  the  eighth  most  lethal  type  of  cancer  in
women  worldwide,  with  over  184,000  fatalities  reported  in
20181. It has a poor prognosis and is usually diagnosed at late
stage,  due  to  lack  of  specific  diagnostic  biomarkers  and
relatively non-specific symptoms. Current diagnostic tests for
ovarian  cancer  include  the  CA-125  blood  test  coupled  with
abdominal/pelvic  ultrasound and computerized tomography
(CT)  scan.  First  line  treatment  of  ovarian  cancer  is  optimal
debulking  of  macroscopic  disease,  generally  followed  by
chemotherapy with carboplatin alone or in combination with
paclitaxel2,3.
The  most  common type  of  ovarian  cancer  is  epithelial
ovarian cancer (EOC), which is divided into 5 main subtypes,
with  differing  histological,  molecular,  and  genetic
characteristics3,4. The most common subtype is high grade
serous  ovarian  cancer  (HGSOC)  which  accounts  for
approximately  70%  of  the  cases,  with  clear  cell  (10%),
endometrioid  (10%),  mucinous  (<  5%),  and  low  grade
serous  cancer  (<  5%)  comprising  the  other  significant
subtypes3,4.  Recent investigations into the pathogenesis of
ovarian  cancer  showed  that  it  primarily  originates  from
different parts of the female reproductive system and involves
cellular  migration to the ovaries.  HGSOC is  identified to
originate from the distal fallopian tube, endometrioid and
clear  cell  cancers  arise  from the endometrium, while  low
grade serous cancer might progress from serous cystadenoma
and serous borderline tumors5.
Multiple drugs have been tested and approved for ovarian
cancer although the response rate for second line therapy is
only  10%–35%  and  different  ovarian  cancer  subtypes
respond  differently  to  drug  treatment.  HGSOC  patients
usually respond well to initial platinum-based therapy, given
their  BRCA and p53 mutations7.  However,  these patients
often present with resistance to initial  therapy after a few
months.
There is increasing interest in the potential use of targeted
inhibitors for the treatment of ovarian cancer. This review
seeks to overview the current clinical and preclinical status of
human epidermal  growth factor  receptor  (HER) targeted
therapy in ovarian cancer, with special emphasis on tyrosine
kinase inhibitors (TKIs).
Human epidermal growth factor
receptors (HERs)
The HER family has been associated with the progression of
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several  cancers  including  breast,  lung  and  colon  cancer8.  In
ovarian  cancer,  amplification,  and/or  high  expression  of
epidermal  growth factor  receptor  (EGFR),  HER2 and HER3
receptors  have  been  implicated  in  the  progression  and
prognosis of the disease9-12.
The HER family of receptors [also known as erythroblastic
leukemia viral oncogene (erbB) family] are present on the
cell surface as monomers, in the absence of ligand activation.
There are four members in this family, EGFR (HER1/erbB1),
HER2  (neu/erbB2),  HER3  (erbB3)  and  HER4  (erbB4)
(Figure 1). With the exception of HER2, ligands bind to their
extracellular domain and form homo- or heterodimers with
other members of the family, preferentially with HER2, since
it  has  the  most  favorable  kinase  activity  and  exists  in  an
activated form13. HER ligands are divided into three groups;
those which bind specifically to EGFR (epidermal growth
factor,  amphiregulin  and  transforming  growth  factor-α),
those  conferring  dual  specificity  to  EGFR  and  HER4
(betacellulin,  heparin-binding EGF,  and epiregulin),  and
those  which  bind  to  HER3  and  HER4  (neuregulins/
heregulins)14.
Upon  receptor  dimerization,  multiple  downstream
pathways  are  activated,  which  regulate  cell  proliferation,
differentiation,  angiogenesis,  survival,  and  cellular
metabolism amongst other functions. Heterodimerization
allows  for  a  myriad of  phosphotyrosine  residues  to  bind,
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Figure 1   Scheme illustrating the downstream signaling of the HER pathway, chiefly the mitogen activated protein kinase (MAPK)/ERK
pathway,  the  phospholipase  Cγ  (PLCγ)  pathway,  the  signal  transducer  and  activation  of  transcription  (STAT)  pathway,  and  the
phosphoinosidyl-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target  of  rapamycin (mTOR) pathway;  where ER=Endoplasmic
Reticulum, Ca2+=Calcium ions
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which  in  turn  increases  the  possibilities  for  signaling
pathways15. These pathways (Figure 1) include the mitogen
activated  protein  kinase  (MAPK)/ERK  pathway,  which
regulates  the growth and development of  cells,  the signal
transducer and activation of transcription (STAT) pathway,
which  governs  cell  proliferation  and  differentiation,  the
phosphoinosidyl-3-kinase  (PI3K)/protein  kinase  B
(AKT)/mammalian target of rapamycin (mTOR) pathway,
which  regulates  cell  survival  and  metabolism,  and  the
phospholipase Cγ (PLCγ) pathway, which controls calcium-
dependent actions13,16,17. In tumorigenesis, mutations within
the components of these pathways can cause cancer cells to
acquire  certain  aptitudes,  including  impartiality  to
proliferation  signals,  circumvention  of  apoptosis,
insensitivity  to  growth  inhibitory  signals,  augmented
replicative potential and the capability to metastasize18.
EGFR (HER1) is a receptor tyrosine kinase comprising an
extracellular ligand-binding domain of 622 residues,  a  23
residue transmembrane domain,  and a large,  522-residue
intracellular domain15. EGFR is normally weakly expressed in
the ovaries, however, several studies have found that EGFR is
highly expressed in ovarian cancer. Immunohistochemical
studies have indicated that 30%–70% of ovarian cancers have
increased EGFR expression19-21. High expression of EGFR is
associated  with  poor,  progression-free  survival  (PFS),
advanced  tumor  grade,  greater  residual  tumor  mass  and
rapid proliferation9,10,12. It has also been suggested that high
EGFR expression  in  the  tumor  stroma is  associated  with
aggressive  clinical  conditions  and  outcome  and  EGFR
upregulation in fibroblasts  is  associated with growth and
migratory abilities of ovarian cancer cells22.
HER2  is  overexpressed  in  approximately  6%–30%  of
ovarian cancer patients10,23  and is initially associated with
DNA amplification and poor prognosis24. Overexpression is
often  detected  in  the  mucinous  (19%)25  and  clear  cell
(14%)26  subtypes.  However,  even  some serous  (3%)  and
endometr io id  ovar ian  cancers  (2%)  have  HER2
overexpression2 7 .  Several  studies  have  associated
overexpression of HER2 with poor prognosis10,28.
HER3 is  expressed as  a  full-length receptor  on the  cell
surface,  in  parallel  with  truncated  intracellular  isoforms.
However,  the activity of  the latter  is  not well  defined29,30.
HER3  lacks  tyrosine  kinase  activity,  hence  it  has  to  be
transphosphorylated by other HER members to promote cell
signaling15.  HER3 is more frequently expressed in ovarian
cancer  (30%–80%)  than  EGFR  and  HER231  and  is  more
common  amongst  borderline  and  early-stage  lesions32.
Among the dimerization possibilities between these proteins,
the most potent signaling complex is generated when HER3
heterodimerizes with HER233.  Increased HER3 expression
has  been  associated  with  poor  clinical  outcome  and  the
average survival time for patients with low HER3 expression
was 3.3 years, in contrast to 1.8 years for patients with high
HER3 expression11. Studies in various cancers have shown
that when HER3 and MET are co-expressed, they are often
associated with either response or resistance to therapy34-36.
Other  studies  have  shown that  high  expression  of  HER3
might  lead  to  HER3-PI3K-Akt  signaling  cascade  in
doxorubicin and cisplatin treated ovarian cancer, which often
results in resistance to therapy37,38.
HER4 is the least understood receptor of the HER family.
It occurs as a spliced isoform, often being processed further
by enzymes into a soluble intracellular domain, which can
disperse to the cell cytoplasm or nucleus39. In breast cancer,
nuclear  localization  of  the  intracellular  domain  in
combination  with  estrogen  expression  predicted  worse
clinical  outcomes  compared  to  membrane  HER4  and
estrogen40. There are conflicting views about the expression
of HER4 in ovarian cancer, with earlier reports suggesting
either decreased or lack of expression of the receptor41, while
more recent studies suggest an increased expression of HER4
in  malignant  tissues  compared  to  normal  tissues31,42,43.
Although the  implication of  HER4 expression in  ovarian
cancer is unclear, two studies found a possible correlation
between HER4 expression and resistance of serous ovarian
cancer to chemotherapy42,44.
Monoclonal antibodies
HER-targeted  monoclonal  antibodies  (mABs),  such  as
trastuzumab  (Herceptin®)  and  pertuzumab  (Perjeta®)  are
recombinant  humanized  mABs,  inhibiting  HER2  extrace-
llularly  with  differing  modes  of  action  (Figure  2).  These
agents  have  shown  favorable  results  in  HER2  positive
cancers,  especially  HER2-positive  breast  cancer,  where  they
are  well  established  as  standard  therapy.  More  recently,
trastuzumab-emtansine  antibody-drug  conjugate  has  been
developed  as  another  option  for  trastuzumab-resistant
disease.  Preclinical in  vitro and in  vivo studies  and  clinical
trials  have  been  focusing  on  the  activity  of  these  mABs  in
ovarian  cancer,  especially  in  selective  subtypes,  particularly
mucinous  cancers,  which  have  HER2  amplification  and
overexpression45,46.
Trastuzumab
Trastuzumab  binds  to  the  juxtamembrane  region  of  the
extracellular  domain  of  HER2,  inhibiting  cleavage  of  the
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extracellular  domain,  obstructing  HER2  homodimerization
as  well  as  inducing  antibody  dependent  cell-mediated
cytotoxicity47,48. Trastuzumab requires HER2 overexpression
for  it  to  be  effective48,49.  The  success  of  trastuzumab  in
clinical trials49-51 has led to its clinical approval in metastatic
breast  cancer  overexpressing  HER2,  as  monotherapy  or  in
combination  with  paclitaxel  depending  on  whether  the
patients previously received chemotherapy regimens for their
metastatic  disease52.  A  phase  II  clinical  trial  of  trastuzumab
involving  41  eligible  ovarian  cancer  patients  with  HER2
overexpression demonstrated an overall response rate (ORR)
of  7.3%,  which  included  one  complete  and  two  partial
responses. The median PFS was two months53.
Pertuzumab
Pertuzumab  acts  by  blocking  the  dimerization  domain  of
HER2,  thus  inhibiting  HER2  heterodimerization48.  Unlike
trastuzumab,  it  does  not  require  HER2  overexpression  to
confer  its  inhibitory  effects54.  Pertuzumab  is  used  to  treat
HER2-positive  metastatic  breast  cancer  patients  who  have
not  been  previously  exposed  to  anti-HER2  therapy  or
chemotherapy for metastatic  disease and is  also used for the
neoadjuvant  treatment  of  HER2-positive  early  stage  breast
cancer55.  In  a  phase  III  clinical  trial  for  breast  cancer
(CLEOPATRA),  the  combination  of  trastuzumab  and
pertuzumab along with docletaxel, showed additional benefit
compared to monotherapy, which has subsequently led to the
approval  of  this  combination  for  HER2-positive  metastatic
breast  cancer56.  A  randomized  phase  II  clinical  trial  with
pertuzumab  showed  better  PFS  (5.3  months)  in  low  HER3
expressed,  platinum-resistant  ovarian  cancer  patients  and
hence it was assessed in a phase III clinical trial (PENELOPE)
in  platinum-resistant  ovarian  cancer  patients  with  low
expression  of  HER357,58.  In  the  PENELOPE  trial,  patients
who received pertuzumab with chemotherapy showed a PFS
of 4.3 months and an ORR of 13.1%, when compared to the
PFS of 2.6 months and ORR of 8.7% in patients who received
placebo  with  chemotherapy58.  In  an in  vivo setting  using
ovarian  cancer  xenograft  mouse  models,  our  group  has
demonstrated  that  the  combination  of  pertuzumab  and
trastuzumab  produces  prolonged  growth  inhibition,  when
compared  to  either  antibody  used  as  a  single  agent59.
Furthermore,  another  preclinical  study  has  suggested  that
trastuzumab  could  also  augment  sensitivity  to  endocrine
therapy in ERα-positive ovarian cancer60.
Trastuzumab-emtansine
Trastuzumab-emtansine  (T-DM1,  Kadcyla®),  is  a  HER2
targeted  mAB  conjugated  to  a  microtubule  inhibitor
(emtansine). T-DM1 acts by binding to HER2, triggering the
endocytosis  of  the  HER2-T-DM1  complex.  Once  in  the
cytoplasm, DM1 is released from the complex, which inhibits
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Figure 2   Site of action of the various TKIs and the relative potency towards the receptor; where +++ is very potent, ++ is potent, + is
mildly potent and – is generally not active.
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microtubule  assembly,  leading  to  cell  death61.  In  a  phase  III
clinical trial for breast cancer, T-DM1 treated cohort showed
a  superior  clinical  outcome  (PFS  9.6  months)  compared  to
patients  who  received  lapatinib  with  capecitabine
(6.4  months)62.  It  was  later  approved  as  monotherapy  for
HER2-positive metastatic breast cancer, which is resistant to
trastuzumab  treatment63.  In  a  recent in  vivo study  by
Menderes  et  al.64,  T-DM1  demonstrated  significant  tumor
growth  inhibition  against  HER2  overexpressing  ovarian
cancer  primary  cell  lines  compared to  either  pertuzumab or
trastuzumab alone or a combination of both. It also reduced
tumor  growth  and  improved  survival  in  xenograft  mod-
els64-66.  This agent was also shown to have similar antibody-
dependent, cell-mediated cytotoxicity as pertuzumab, trastu-
zumab  and  their  combination64.  Another  study  demonst-
rated  their  excellent  inhibitory  activity  against  both
subcutaneous and intraperitoneal growth of the SKOV3 in an
ovarian cancer xenograft model67.
TKIs
TKIs  are  small  drug  molecules  that  inhibit  tyrosine  kinases.
Tyrosine  kinases  include  the  HER  family,  vascular
endothelial  growth factor receptors (VEGF), platelet-derived
growth  factor  receptors  (PDGFR),  and  also  non-receptor
tyrosine kinases BCR-ABL and KIT68,69. Tyrosine kinases are
enzymes  that  catalyze  the  transfer  of  phosphate  from
adenosine triphosphate (ATP) onto target proteins to elicit a
response. There are three types of TKIs. Most small molecule
TKIs are type I, which compete with ATP by binding to ATP
binding  sites  on  the  active  conformation  of  the  receptors,
thereby interfering with the action of tyrosine kinases69. Type
II  TKIs  bind to the inactive  conformation of  a  kinase,  while
type  III  allosteric  inhibitors  bind  to  sites  distant  from  the
active  site70.  To  date,  a  few  TKIs  have  been  evaluated  in
ovarian  cancer  patients  that  are  described  below  (Table  1,
Figure 2). These include the first generation EGFR inhibitors,
gefitinib  and  erlotinib,  which  have  shown  clinical  efficacy
against  mutant  EGFR  lung  cancer.  Since,  a  resistance
mutation  develops  frequently  at  T790M  upon  treatment,
covalent irreversible second generation TKIs were developed.
These consist of afatinib and neratinib that are active against
this  mutation.  Other  HER  inhibitors  were  developed  with
broader  inhibitory  activity  across  multiple  HER  family
members  (pan-inhibitors)  and  these  include  lapatinib  and
canertinib  as  early  developed  inhibitors,  followed  by
neratinib,  sapitinib,  and dacomitinib.  Finally,  multi-targeted
TKIs  that  target  the  HER  family  among  other  targets  (e.g.,
PDGFR, VEGFR, etc.) include vandetanib and leflunomide.
Reversible inhibitors
Gefitinib
Gefitinib (Iressa®, ZD-1839) is a type I quinazoline derivative
TKI,  reversibly  selective  for  EGFR.  Gefitinib  is  marketed for
monotherapy of locally advanced or metastatic NSCLC and is
most  effective  in  cancers  with  mutation  or  increased  EGFR
copy number81.  When evaluated  in  an  ovarian  cancer  phase
II  trial,  gefitinib showed a limited response rate in platinum
pre-treated  ovarian  cancer  patients,  with  only  one  out  of
twenty-seven patients having an ORR of 4%82. However, this
cancer was the one in this cohort harboring a mutation in the
catalytic  region  of  EGFR,  consistent  with  data  for  NSCLC.
Another  phase  II  clinical  trial  combining  gefitinib  with
tamoxifen  in  refractory  or  resistant  ovarian  cancer  patients,
did not demonstrate any advantageous tumor responses with
median  time-to-progression  being  58  days83.  Preclinical
studies  in  ovarian  cancer  demonstrate  that  combining
gefitinib  with  cisplatin,  increases  the  efficacy  of  cisplatin,
mainly due to the inhibition of downstream EGFR signaling
and blocking DNA repair mechanisms84.
Erlotinib
Erlotinib  (Tarceva®,  OSI-774)  is  a  quinazoline  derivative,
which  reversibly  inhibits  EGFR.  It  is  indicated  as  a  first  line
therapy for NSCLC and in combination with gemcitabine for
pancreatic  cancer.  Erlotinib  has  shown enhancement  of  PFS
compared  to  chemotherapy  (13.1  months  vs.  4.6  months,
respectively)  in  chemotherapy-naive  NSCLC  patients,
harboring  EGFR  mutations85.  An in  vivo study  in  ovarian
cancer  expressing  high  EGFR  demonstrated  that  a  combin-
ation  of  erlotinib  with  olaparib,  a  PARP  inhibitor,  had  a
greater  tumor  suppressive  effect  than  monotherapy86.  A
phase  II  study combining erlotinib  with carboplatin  showed
that  this  combination  was  more  effective  in  ovarian  cancer
patients  with  platinum-sensitive  disease  compared  to
platinum-resistant  disease  with  57%  and  7%  objective
response  rates,  respectively.  However,  the  contribution  of
erlotinib  in  this  combination  is  unclear87.  Another  phase  II
study  assessing  the  pathologic  complete  response  (pCR)  of
ovarian  cancer  patients  administered  with  a  combination  of
carboplatin,  paclitaxel,  and  erlotinib,  resulted  in  pCR  of
around  30%,  which  was  not  an  improvement  when
compared  to  previous  results88.  Continuous  infusion  of
topotecan with erlotinib was studied in a phase II trial, where
only  1  out  of  6  patients  showed  a  satisfactory  partial
response89.  An  exploratory  phase  II  clinical  trial  involving
bevacizumab  and  erlotinib  determined  that  high  levels  of
VEGF-A  caused  bevacizumab  resistance,  while  erlotinib  did
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not seem to contribute to the efficacy of the combination90. A
randomized  phase  III  study  evaluated  the  efficacy  of
administering  erlotinib  to  patients  with  ovarian  cancer  after
first line chemotherapy. The median PFS in patients receiving
erlotinib and placebo was 12.7 and 12.4 months, respectively,
concluding that erlotinib does not render pre-treated ovarian
cancer patients with additional benefits91. In extension to this
phase  III  clinical  trial,  a  tissue  biomarker  study  concluded
that increased EGFR gene copy number led to worse overall
survival and PFS92.
Lapatinib
Lapatinib (Tyverb®,  GW-572016) is  an oral  competitive TKI
inhibitor selective for EGFR and HER2. It is recommended in
HER2 overexpressing breast cancer. Preclinical data indicates
that  lapatinib  is  effective  when  HER2  is  overexpressed  and
most likely homodimerized78.  In breast  cancer clinical  trials,
lapatinib  has  shown  better  inhibition  of  tumors  expressing
HER2  instead  of  EGFR78,93.  In  a  phase  I  study  in  ovarian
cancer,  while  assessing  lapatinib  in  combination  with
carboplatin  many  non-dose  limiting  toxicities  were  noticed
and 6 out of 11 patients had PR or stable disease94, while in a
phase  II  trial  (LapTop)  assessing  lapatinib  with  topotecan,
only  20%  of  patients  experienced  benefit.  However,
considerable  hematologic  adverse  effects  were  observed  in
this  trial95,96.  In  another  phase  II  study  in  recurrent  ovarian
cancer,  the  median  PFS  was  1.8  months,  OS  was  10.5
months, and only 2 out of 25 patients had PFS at 6 months,
while  there  was  no  ORR,  which  might  be  due  to  low EGFR
and HER2 expression97.
Sapitinib
Sapitinib  (AZD  8931)  is  a  type  I,  reversible,  equipotent
inhibitor  of  EGFR,  HER2  and  HER3  receptor  signaling,
especially  when  EGFR  is  highly  expressed  and  there  is  no
HER2  overexpression78,98.  In  fact,  sapitinib  has  shown
enhanced  tumor  growth  inhibition  against  EGFR-driven
xenograft  tumors  when  compared  to  lapatinib78.  Preclinical
Table 1   HER-targeted TKIs evaluated in preclinical models of ovarian cancer
TKI Chemicalstructure Pharmacology Clinical status
IC50: EGFR
(nM)
IC50: HER2
(nM)
IC50: others
(nM) Reference
Afatinib
(BIBW2992)
Potent and irreversible
inhibitor of EGFR/HER2
including erlotinib-resistant
EGFR T790 M71,72
Marketed for EGFR
mutation positive lung
cancer
0.5 14 - 73
Canertinib
(CI-1033)
Irreversible non-selective
EGFR family inhibitor, with an
additional benefit of
blocking mutant EGFRvIII74
Reached phase II;
discontinued lately
by Pfizer
1.8 11 HER4: 27 75
Dacomitinib
(PF00299804)
Irreversible pan-HER
inhibitor, especially EGFR
Phase III clinical trials 6.0 45.7 HER4: 73.7 75
Erlotinib
(OSI-774)
Specific and reversible
inhibitor of EGFR
Marketed for NCSLC and
pancreatic cancer
0.5 512 HER4: 790 75
Gefitinib
(ZD-1839)
Specific and reversible
inhibitor of EGFR
Marketed for NCSLC 3.1 343 HER4: 476 75
Lapatinib
(GW-572016)
Reversible and specific
inhibitor to EGFR and HER276
Marketed for HER2
overexpressing breast
cancer
10.8 9.2 HER3: 13,
HER4: 367
77,78
Neratinib
(HKI-272)
Potent irreversible, pan-HER
(ie, HER 1, 2, and 4) TKI, with
low molecular weight79
Marketed for adjuvant
treatment of HER2
overexpressing breast
cancer
92 59 KDR: 800,
src: 1400
80
Sapitinib
(AZD-8931)
Equipotent inhibitor of EGFR,
HER2 and HER378
Phase II clinical trials 4 3 HER3: 4 78
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studies  suggest  that  sapitinib  favors  HRG-induced
HER2/HER3  heterodimers78.  It  has  also  demonstrated  its
ability  to  inhibit  proliferation  through  pERK  and  pAkt
pathways,  and  induce  apoptosis  through  M30  and  cleaved
caspase-378.  In  xenograft  models  of  inflammatory  breast
cancer,  sapitinib  alone significantly  inhibited tumor growth,
however,  the  combination  of  paclitaxel  and  sapitinib  was
more  effective  than  either  agent  alone98.  Sapitinib  has  been
tested in 8 ovarian cancer patients amongst others, in a phase
I  clinical  trial,  to  assess  the  maximum tolerated dose,  which
was established to be 240 mg twice, daily99.
Irreversible inhibitors
Afatinib
Afatinib  (Gilotrif®,  Giotrif®,  BIBW-2992)  is  a  type  I  anilino-
quinazoline derivative TKI inhibitor, which irreversibly binds
to EGFR, HER2 and HER4100. It is currently approved for the
treatment  of  mutated  EGFR  non-small  cell  lung  cancer
(NSCLC). Afatinib has not been extensively tested in ovarian
cancer  clinical  trials.  A  phase  I  dose  escalation  study,  which
included  four  ovarian  cancer  patients,  showed  promise
clinically as indicated by stable disease101,102. In breast cancer,
afatinib  treatment  was  effective,  however,  it  produced many
unwanted side  effects  in  patients103,104.  In  an ovarian cancer
preclinical  study,  afatinib  reversed  the  ATP  binding  cassette
(ABC)  mediated  multidrug  resistance  to  paclitaxel  and
adriamycin  and  also  increased  the  apoptotic  efficacy  of
paclitaxel  in  ABCB1  overexpressing  tumors105.  In  breast
cancer,  it  was  also  found  that  afatinib  overcomes  HERT798I-
mediated  neratinib  resistance106. In  vivo,  afatinib  with
docetaxel  showed  better  response  in  tumor  size  reduction,
than  either  drug  as  a  single  agent107. In  vitro studies  using
ovarian  cancer  cell  line  models  showed  that  afatinib  is
effective  in  inhibiting  migration  and  proliferation108.  It  was
also  found  to  be  effective  in  inhibiting  basal  and  heregulin-
induced EGFR, HER2, Akt and ERK phosphorylation108.
Canertinib
Canertinib  (CI-1033,  PD-183805)  is  a  4-anilinoquinazoline,
irreversible,  pan-HER  TKI,  which  reached  phase  II  clinical
trials.  However,  it  was  recently  withdrawn109. In  vivo,
canertinib showed potent inhibitory effects in ovarian cancer
cell  lines,  especially  when combined with a  c-MET inhibitor
(PHA665752),  which  further  reduced  phosphorylation  and
total expression of signaling proteins108,110,111. A randomized
phase  II  clinical  trial  in  platinum  resistant  or  refractory
ovarian  cancer  patients  resulted  in  disease  stability  in  about
30%  of  the  patients  and  a  one-year  survival  rate  of  around
37%.  However,  there  were  no  complete  or  partial
responses112. Studies suggest that high levels of HER and low
levels  of  HER  autocrine  ligands  lead  to  canertinib
resistance113.
Neratinib
Neratinib  (Nerlynx®,  HKI-272)  is  an  oral,  irreversible  pan-
HER  inhibitor,  which  has  been  recently  approved  for  the
adjuvant  treatment  of  early  stage  HER2-positive  breast
cancer114,  after a phase III study indicated a 2-year, invasive,
disease-free  survival  rate  of  94%,  when  administered  after
chemotherapy  and  trastuzumab  adjuvant  therapy115.  In  a
phase  II  study  assessing  neratinib  in  advanced  NSCLC,
patients  with  T790M  EGFR  mutation  did  not  respond  to
therapy, however, partial response or disease stabilization was
seen  in  patients  with  G719X  mutated  EGFR116.  Overall,
previously  treated  patients  or  TKI-naïve  patients  did  not
benefit notably from neratinib treatment. One of the reasons
for  this  could  be  low  bioavailability  due  to  dose  reductions
prompted  by  toxicity116.  In  HER2-positive  breast  cancer,
neratinib as a single agent was well  tolerated and has shown
substantial  clinical  activity  in  trastuzumab-naïve  patients,
with  a  16-week  PFS  rate  of  78%  and  median  PFS  of  39.6
weeks  versus  16-week  PFS  rate  of  59%  and  median  PFS  of
22.3  weeks  in  trastuzumab  pre-treated  patients79.  Other
clinical  trials  in  breast  cancer  assessed  neratinib  in
combination  with  temsirolimus,  vinorelbine,  paclitaxel  with
or  without  trastuzumab  and  capecitabine,  all  of  which  were
well tolerated by patients and had anti-tumor properties117-121.
Neratinib  has  demonstrated  pre-clinical  efficacy  in  ovarian
cancer,  especially  in HER2-amplified carcinosarcoma,  where
it  inhibits  proliferation  and  tumor  growth122,  as  well  as
decreases  phosphorylation  of  transcription  factor  S6  and
causes  cell  cycle  arrest  in  the  G0/G1  phase123.  There  is
currently a phase II clinical trial assessing neratinib efficacy in
HER2-positive solid tumors (SUMMIT Trial) with mutations
in  EGFR,  HER2  or  HER3,  including  ovarian  cancer
(NCT01953926).  This  trial  included  four  evaluable  ovarian
cancer  patients  of  whom one  had stable  disease,  while  three
had disease progression124.
Other HER-targeted TKIs investigated in
clinical trials
Dacomitinib (PF00299804), a recently developed irreversible
pan-HER  receptor  inhibitor,  has  demonstrated  interesting
anti-proliferative  activity  against  chemoresistant  ovarian
cancer  cell  lines125.  One  ovarian  cancer  patient  showed
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response  in  a  phase  I  clinical  trial  of  dacomitinib  in
combination  with  anti-IGFIR  antibody  figitumumab126.
Several  multi-targeted  TKIs  with  broad-spectrum  activity
including  the  HER  family  are  undergoing  evaluation.
Vandetanib  (ZD6474)  is  a  drug  that  inhibits  EGFR,  VEGF
receptor  and  Ret  signaling  and  has  been  tested  as
monotherapy  in  an  ovarian  cancer  trial  where,  despite
decreasing  EGFR  phosphorylation,  it  demonstrated  little
efficacy127.  Leflunomide  is  an  inhibitor  of  EGFR,  PDGFR,
and FGFR and in two phase II trials, 1 out of 8 (12.5%) and 1
out of 15 (7%) ovarian cancer patients demonstrated partial
response128,129.
Biomarkers of sensitivity and
resistance to TKIs in ovarian cancer
In  breast  and  lung  cancers,  informative  biomarkers  of
sensitivity to HER TKIs include overexpression of HER2 and
mutation of EGFR. In breast cancer, HER2 overexpression is
an effective  biomarker  of  sensitivity  to  HER2-targeted TKIs,
such  as  lapatinib.  Preclinical  studies  of  T-DM1  in  ovarian
cancers  suggest  that  minimal  expression  of  HER2  was
essential for anti-tumorigenic properties of T-DM1 in model
systems66.  Analysis  of  a  series  of  ovarian  cancer  xenograft
models  demonstrated the curative  potential  of  trastuzumab/
pertuzumab  combination  in  cancers  with  amplification  and
overexpression of  HER2.  Currently  there  is  less  information
available regarding the association of HER2 expression levels
and  TKIs,  in  ovarian  cancer59,60.  Interestingly,  there  is  one
case  report  of  dramatic  remission  of  a  chemotherapy-
resistant  ovarian  cancer  to  trastuzumab,  which  was  HER2-
negative suggesting that, the factors governing responsiveness
in ovarian cancer might differ from those in breast cancer130.
The  mutated  form  of  EGFR  with  deletions  in  exon  19
indicates sensitivity to TKIs such as erlotinib and gefitinib, in
NSCLC131.  However,  the  importance  of  EGFR  mutations  in
ovarian  cancer  is  still  not  well  researched  since  the  occurr-
ence of these mutations is much lower. As mentioned above,
in  a  phase  II  trial  of  gefitinib  in  27  ovarian  cancer  patients,
the  single  patient  showing  response  did  contain  an  EGFR
mutation (2235del15; E746-A750del) in the catalytic domain
consistent  with  this  molecular  feature  being  an  indicator  of
sensitivity82.  This  requires  further  validation  in  future
studies.
The  importance  of  mutations  in  HER2  and  HER3  for
sensitivity  to  pan-HER  inhibitors,  is  under  clinical
investigation  at  present  and  a  basket  trial  (SUMMIT)
investigating neratinib treatment in multiple cancers with
mutations, has been reported124.
As observed with other chemotherapeutic drugs, resistance
to TKIs is inevitable132. Mechanisms of resistance to EGFR-
specific  TKIs  can include abnormalities  in HERs,  such as
HER2  overexpression  and  mutations  like  EGFRvIII  and
HER2L869R106,133  and  secondary  EGFR  mutations  in
T790M134,  L747S,  D761Y,  and  T854A135.  Downstream
signaling  pathways  that  are  frequently  modified  include
mutations  in  KRAS,  BRAF,  PIK3CA,  and  PTEN136-138.
Alternative  pathways  that  can  bypass  control  include
aberrant activation of MET and HGF139,140, modifications in
VEGF  receptors  which  trigger  vascular  permeability,  in
platelet-derived growth factors that regulate angiogenesis and
in interleukin-6 that controls inflammatory processes132-134.
For other TKIs, overexpression of ABC resulting in low drug
concentration in cells due to decreased uptake and increased
efflux of the drug141 also contribute in resistance to therapy.
Future research
Combination therapy
Research  in  various  cancers  show  that  the  combination  of
TKIs  with  chemotherapy,  radiation,  or  mABs  significantly
inhibits tumor growth, without additional toxic effects, since
they have different inhibitory profiles. For instance, lapatinib
is  administered  in  combination  with  either  capecitabine/
trastuzumab/aromatase  inhibitor  in  HER2-positive  breast
cancers.  Synergistic  drug  combinations  can  be  achieved  in
two ways: vertically, which involves similar doses as monoth-
erapy,  and  horizontally,  in  which  the  concentration  of  the
dose  is  decreased  downwards142.  To  date,  in  ovarian  cancer,
there  are  no  established  combination  strategies  involving
TKIs.  In  ovarian  cancer,  only  the  mAB  bevacizumab  is
approved  to  be  used  in  combination  with  paclitaxel  and
carboplatin. In a phase II  ovarian cancer study, the combin-
ation  of  pertuzumab  and  gemcitabine  showed  improved
overall PFS when compared to gemcitabine and placebo57. In
breast  cancer,  the  combination  of  pertuzumab  and
trastuzumab  has  shown  significant  advantages  over
monotherapy.  However,  the  combination  of  these  mABs  in
ovarian  cancer  has  only  been  studied in  vivo,  which  has
shown promising results59, and thus might be worth looking
at  clinically.  Additionally,  the  combination  of  mABs  and
TKIs has not been clinically studied so far, in ovarian cancer.
The  combination  of  HER-targeted  inhibitors  with  Poly
(ADP-ribose)  polymerase  (PARP)  inhibitors  might  prove
useful  in  the  treatment  of  ovarian  cancer,  since,  recent in
vitro studies  combining  a  TKI  with  a  PARPi  showed
synergistic  growth  inhibitory  effects143.  Computational
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biology has developed in recent years and offers the potential
of  precision  medicine.  Molecular  anomalies  can  now  be
detected  when  screening  through  molecular  information,
which  could  identify  individual  patient  appropriate
medication . Hence, more pre-clinical bioinformatics studies
need  be  conducted  to  investigate  the  effects  of  therapy  on  a
molecular basis.
Chemosensitive versus chemoresistant
phenotypes
HGSOC  usually  responds  well  to  initial  ovarian  cancer
therapy,  with  response  rates  as  high  as  85%7.  This  is
frequently due to the fact that HGSOC has BRCA mutations.
First-line  chemotherapy  acts  by  damaging  DNA  strands;
BRCA  acts  to  repair  DNA,  however,  given  that  HGSOC
frequently  lacks  BRCA  function,  DNA  strands  cannot  be
repaired, which consequently leads to the efficacy of primary
chemotherapy  in  HGSOC.  However,  HGSOC  cells  through
further mutation can restore BRCA function, which is one of
the leading causes of resistance to initial chemotherapy144.
It  is  often  acknowledged  that  ABC transporters  play  a
pivotal role in resistance to first line chemotherapy. In fact,
ABCB1, ABCB4, and ABCG2 were significantly up-regulated
in cisplatin and paclitaxel resistant ovarian cancer cells145.
Pertuzumab  in  a  clinical  trial  of  chemoresistant  disease
showed that  the  mAB demonstrated  possible  anti-tumor
activity  when  combined  with  either  gemcitabine  or
paclitaxel57,58,  while  novel  TKIs  that  target  multiple  sites
often demonstrate their ability to reverse ABC-mediated drug
resistance105,146-148. Hence, mABs and TKIs might be more
active  in  chemoresistant  ovarian  cancer  than  in  the
chemosensitive type.
Conclusions
Ovarian cancer is a complex disease, with multiple molecular
profiles.  It  frequently  becomes  resistant  after  initial  therapy
necessitating the development of new strategies.
The use of HER-targeted therapy continues to be assessed
in this disease, since it might have value for selective patients
and pre-clinical data supports the potential of this approach.
Only a limited number of phase II trials have been completed
in ovarian cancer and while response rates are low, there are
frequent good percentages of stable disease. The pan-HER
TKIs may have broader efficacy and utility  than the early
EGFR-targeted TKIs, which are dependent on the presence of
mutations  (are  uncommon  in  ovarian  cancer).  Further
biomarker studies are now required to help identify the most
sensitive ovarian cancers and combination strategies require
further development.
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